MARKET

GANX

GANX

Gain Therapeutics, Inc.
NASDAQ
2.110
-0.090
-4.09%
After Hours: 2.160 +0.05 +2.37% 18:47 03/14 EDT
OPEN
2.250
PREV CLOSE
2.200
HIGH
2.290
LOW
2.100
VOLUME
333.51K
TURNOVER
--
52 WEEK HIGH
4.740
52 WEEK LOW
0.8900
MARKET CAP
55.97M
P/E (TTM)
-1.8661
1D
5D
1M
3M
1Y
5Y
1D
GAIN THERAPEUTICS INC: INTERIM DATA FROM PHASE 1B TRIAL ARE ANTICIPATED AT END OF 2Q 2025
Reuters · 2d ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Barchart · 2d ago
Weekly Report: what happened at GANX last week (0303-0307)?
Weekly Report · 6d ago
Scotiabank Initiates Coverage of Gain Therapeutics (GANX) with Sector Outperform Recommendation
NASDAQ · 03/08 12:06
Gain Therapeutics Price Target Announced at $12.00/Share by Scotiabank
Dow Jones · 03/07 22:56
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
TipRanks · 03/07 14:52
Gain Therapeutics initiated with an Outperform at Scotiabank
TipRanks · 03/07 12:07
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
Barchart · 03/06 06:55
More
About GANX
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Webull offers Gain Therapeutics Inc stock information, including NASDAQ: GANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GANX stock methods without spending real money on the virtual paper trading platform.